Date: 26 November 2013
renal transplant patient
Copyright:
Kindly provided by Iván Solano Leiva, Infectious Diseases MD, Instituto Salvadoreno del Seguro Social, El Salvador.
Notes:
A 54 yr old male patient who underwent a renal transplant one year earlier. The patient noticed a lesion on left plantar region, it was not painful but was slowly enlarging (over 9 months). In the latter 3 months the lesion became slightly purulent. Multiple cycles of antibiotics gave no improvemnt. Culture of the discharge produced Aspergillus niger. The final diagnosis of this patient was Aspergillus osteomyelitis. The patient was treated with voriconazole orally 200 mg twice daily.
Images library
-
Title
Legend
-
Patient with chronic productive cough, chest pain and ABPA, unable to take itraconazole or nebulised amphotericin B. Smokes at least 40 roll up cigarettes a day.
, 
-
Laryngeal aspergillosis, probably related to inhaled corticosteroids.
, 
, 
, 
-
VL-2397 (formerly known as ASP2397) is a novel antifungal drug initially developed by our partner, Astellas Pharma. This drug was isolated from a leaf litter fungus Acremonium species collected in a Malaysian national park. Astellas presented two posters at the 2014 ICAAC meeting which described the in vitro and the in vivo antifungal activities of this drug. The differentiating attributes from the preclinical data of VL-2397 include:
- A novel mechanism of action, with a potential to be complementary or synergistic with the existing classes of antifungals.
- Rapid fungal cell kill activity demonstrated in preclinical models, which was faster than marketed antifungals.
- Activity against azole-resistant fungal species.
- Low propensity for P450 drug-drug interactions.
-
SCY-078, new orally available beta-1,3-d-glucan synthase inhibitor, Formely MK-3118.
-
Pt DSM Community acquired primary Aspergillus pneumonia. Two x-rays taken on 02/02/2010 then 05/03/2010
, 
, 
